Meet the people who make Transposagen a leader in genetically modified animal models, cell engineering services, and gene editing tools.
Mr. Crawford has Directed the Sales, Marketing, and Business Development Divisions at Transposagen. He has experience product development, licensing, technology and patent evaluation. He contributed to nearly all aspects of Transposagen’s rise from pre-revenue start-up to $100M+ valuation including its spin-out companies Poseida Therapeutics and Hera BioLabs. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Masters in Biotechnology from University of Pennsylvania.
Dr. Gary Woodnutt
Chief Scientific Officer
Dr. Gary Woodnutt is the Chief Scientific Officer for Transposagen bringing to the role extensive experience in drug discovery and pharmaceutical research. Prior to joining Transposagen, Dr. Woodnutt served as CSO of Lpath where he led all Discovery and Development activities concerning the exploitation of monoclonal antibodies to bioactive lipids. Dr. Woodnutt served as the Vice President, Open Innovation at Pfizer/CovX from 2012 to 2013, but his primary role at CovX, from 2006 to 2012, was as Vice President of Biology Research. From 2002 to 2006, Dr. Woodnutt was the Senior Vice President of Pharmaceutical Research and Development for Diversa Corporation. He began his career in the pharmaceutical industry with Glaxo SmithKline Pharmaceuticals, where he was employed for more than 20 years and rose to the position of Vice President and Head of Biology in the Antimicrobial and Host Defense Group. Dr. Woodnutt received his Ph.D. in biochemistry/physiology from the University of Reading, and he has authored numerous scientific articles.